Acacia Subsidiary Acquires Patents on Fluorescence Microscopy

  Acacia Subsidiary Acquires Patents on Fluorescence Microscopy

Business Wire

NEWPORT BEACH, Calif. -- October 15, 2013

Acacia Research Corporation (NASDAQ: ACTG) announced today that a subsidiary
has acquired 13 US and foreign patents and applications on fluorescence
microscopy.

“Acacia continues to increase the number of leading patent portfolios in the
medical device and life sciences space,” commented Matt Vella, CEO.
“Fluorescence microscopy is of key relevance to the life sciences because it
enables three-dimensional imaging of cellular constituents with unrivaled
specificity.”

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation’s subsidiaries partner with inventors and patent
owners, license the patents to corporate users, and share the revenue.

Information about Acacia Research Corporation and its subsidiaries is
available at and www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This news release contains forward-looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act
of 1995. These statements including those of Matthew Vella relating to our
licensing success, the number of technology companies selecting us as their
partner, and the growth of our base of future revenues are based upon our
current expectations and speak only as of the date hereof. Our ability to
become the licensing partner for companies, and our ability to grow our base
of future revenues by adding new patent portfolios may differ materially and
adversely from that expressed in any forward-looking statements as a result of
various factors and uncertainties, including the economic slowdown affecting
technology companies, the ability to successfully develop licensing programs
and attract new business, rapid technological change in relevant markets,
changes in demand for current and future intellectual property rights,
legislative, regulatory and competitive developments addressing licensing and
enforcement of patents and/or intellectual property in general, and general
economic conditions. Our Annual Report on Form 10-K, recent and forthcoming
Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A,
and other SEC filings discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.

Contact:

Acacia Research Corporation
Rob Stewart
Investor Relations
Tel 949-480-8300
Fax 949-480-8301
or
Media Contact:
SpecOps Communications
Adam Handelsman
President & Founder
212-518-7721
adam@specopscomm.com